---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104557"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:56:00.421196+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Relay reports positive interim RLY-2608 data: 9.2mo PFS in PI3Kα-mutated breast cancer

## Summary
- Median PFS 9.2 months (all mutations) and 10.3 months (kinase mutations) at RP2D in heavily pre-treated patients without PTEN/AKT co-mutations.
- ORR of 33% overall and 53% in kinase mutations; CBR 57%; tumor reductions in 73% of measurable patients.
- Favorable tolerability: 95% median dose intensity, only 2 discontinuations due to TRAEs, 1 Grade 3 hyperglycemia, no Grade 4-5 TRAEs.
- Lirafugratinib: FDA suggests file NDA in cholangiocarcinoma first, then tumor-agnostic sNDA; company seeks global partner.
- Cash runway ~$688M into H2 2026; plan to initiate 2L pivotal study of RLY-2608 in 2025.

## SEC filing metadata
- accession: 0000950170-24-104557
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017024104557/0000950170-24-104557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017024104557/rlay-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104557
- JSON: https://secwatch.observer/filing/0000950170-24-104557.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.